Patents by Inventor David Dornan

David Dornan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220226491
    Abstract: The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 21, 2022
    Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Justin Kenkel, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
  • Publication number: 20220226492
    Abstract: The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds human epidermal growth factor receptor 2 (“HER2”) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 21, 2022
    Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
  • Publication number: 20220195066
    Abstract: The invention provides immunoconjugates of Formula I comprising an anti-CEA antibody linked by conjugation to one or more 8-Het-2-aminobenzazepine derivatives. The invention also provides 8-Het-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.
    Type: Application
    Filed: December 9, 2021
    Publication date: June 23, 2022
    Applicant: BOLT BIOTHERAPEUTICS, INC.
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Marcin Kowanetz, Romas Kudirka, Arthur Lee, William Mallet, Brian Safina, Matthew Zhou
  • Publication number: 20220152215
    Abstract: The invention provides an immunoconjugate of formula (I) or (II) Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds carcinoembryonic antigen (“CEA”) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 19, 2022
    Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Marcin Kowanetz, Romas Kudirka, Arthur Lee, William Mallet, Brian Safina, Matthew Zhou, Edgar George Engleman
  • Publication number: 20220153849
    Abstract: The invention relates to dendritic cell-associated C-type lectin 2 (Dectin-2) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of providing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods of stimulating an antigen presenting cell.
    Type: Application
    Filed: February 3, 2022
    Publication date: May 19, 2022
    Applicant: Bolt Biotherapeutics, Inc.
    Inventors: Shelley Erin Ackerman, David Dornan, Karla A. Henning, Justin A. Kenkel
  • Publication number: 20220143012
    Abstract: The invention provides a macromolecule-supported compound of formula (I) or (II). Macromolecule-supported compounds of the invention, comprising macromolecular support linked to one or more TLR agonists, are recognized by TLRs (e.g., TLR7 and/or TLR8) with high affinity providing utility in therapeutics, diagnostics, and chemical assays. The invention further provides compositions comprising and methods of treating cancer with the macromolecule-supported compounds.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 12, 2022
    Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Justin Kenkel, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
  • Publication number: 20200247887
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: October 11, 2019
    Publication date: August 6, 2020
    Applicant: Genentech, Inc.
    Inventors: Yvonne CHEN, Mark DENNIS, David DORNAN, Kristi ELKINS, Jagath Reddy JUNUTULA, Andrew POLSON, Bing ZHENG
  • Publication number: 20200079852
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: November 21, 2019
    Publication date: March 12, 2020
    Applicant: Genentech, Inc.
    Inventors: Yvonne CHEN, Mark DENNIS, David DORNAN, Kristi ELKINS, Jagath Reddy JUNUTULA, Andrew POLSON, Bing ZHENG
  • Patent number: 10544218
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: January 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
  • Patent number: 10494432
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: December 3, 2019
    Assignee: Genentech, Inc.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
  • Publication number: 20190276550
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: August 22, 2013
    Publication date: September 12, 2019
    Applicant: Genentech, Inc.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
  • Patent number: 10316049
    Abstract: Compounds having the following formula (I) and methods of their use and preparation are disclosed:
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: June 11, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhimin Du, David Dornan, Juan A. Guerrero, Joshua A. Kaplan, John E. Knox, Devan Naduthambi, Barton W. Phillips, Susanna Y. Stinson, Chandrasekar Venkataramani, Peiyuan Wang, William J. Watkins
  • Patent number: 9896506
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals, including immunoconjugates comprising anti-CD79b cysteine-engineered antibody huMA79b.v28, and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: February 20, 2018
    Assignee: GENENTECH, INC.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
  • Publication number: 20180042905
    Abstract: The present invention relates to novel methods of treating Hepatitis B Virus by administering a KDM5 inhibitor.
    Type: Application
    Filed: August 29, 2017
    Publication date: February 15, 2018
    Inventors: Esmeralda Aguayo, Todd Appleby, Gabriel Birkus, Guofeng Cheng, David Dornan, Tetsuya Kobayashi, Christopher Charles Mello, Uli Schmitz, Madeleine Willkom, Mei Yu
  • Publication number: 20170174713
    Abstract: Compounds having the following formula (I) and methods of their use and preparation are disclosed:
    Type: Application
    Filed: December 15, 2016
    Publication date: June 22, 2017
    Inventors: Zhimin Du, David Dornan, Juan A. Guerrero, Joshua A. Kaplan, John E. Knox, Devan Naduthambi, Barton W. Phillips, Susanna Y. Stinson, Chandrasekar Venkataramani, Peiyuan Wang, William J. Watkins
  • Patent number: 9617600
    Abstract: The invention provides methods and kits useful for predicting or assessing responsiveness of a patient having B-cell lymphoma to treatment with anti-CD40 antibodies.
    Type: Grant
    Filed: April 17, 2010
    Date of Patent: April 11, 2017
    Assignee: Genentech, Inc.
    Inventors: David Dornan, Bart Burington
  • Publication number: 20170058032
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: November 11, 2016
    Publication date: March 2, 2017
    Applicant: Genentech, Inc.
    Inventors: Yvonne CHEN, Mark DENNIS, David DORNAN, Kristi ELKINS, Jagath Reddy JUNUTULA, Andrew POLSON, Bing ZHENG
  • Publication number: 20160303095
    Abstract: The present invention relates to novel methods of treating Hepatitis B Virus by administering a KDM5 inhibitor.
    Type: Application
    Filed: April 13, 2016
    Publication date: October 20, 2016
    Inventors: Esmeralda Aguayo, Todd Appleby, Gabriel Birkus, Guofeng Cheng, David Dornan, Tetsuya Kobayashi, Christopher Charles Mello, Uli Schmitz, Madeleine Willkom, Mei Yu
  • Publication number: 20150314016
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: June 9, 2015
    Publication date: November 5, 2015
    Applicant: GENENTECH, INC.
    Inventors: Yvonne CHEN, Mark DENNIS, David DORNAN, Kristi ELKINS, Jagath Reddy JUNUTULA, Andrew POLSON, Bing ZHENG
  • Patent number: RE48558
    Abstract: The present invention is directed to compositions of matter comprising immunoconjugates comprising an anti-CD79b antibody comprising: (i) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 194), (ii) an HVR-L2 sequence of AASNLES (SEQ ID NO: 195), (iii) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 196), (iv) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 202), (v) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 203), and (vi) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 204) and to methods of using those compositions of matter for the treatment of hematopoietic tumor in mammals.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: May 18, 2021
    Assignee: GENENTECH, INC.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng